In the following video, Motley Fool health-care analyst David Williamson highlights one pharmaceutical company that has no interest in organic growth. Valeant Pharmaceuticals (NYSE:VRX) is continuing its growth-through-acquisition strategy with the purchase of Obagi Medical Products (NASDAQ:OMPI), its 21st acquisition since 2011, for $344 million. David tells investors why this is a win for both parties, and how they should think of the investing thesis behind Valeant.

David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.